View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2022

EC grants approval for Pfizer’s Lorviqua to treat advanced lung cancer

In a Phase III trial, Lorviqua was shown to lower the disease progression or mortality risk by 72% versus treatment with Xalkori.

The European Commission (EC) has granted marketing authorization for Pfizer’s Lorviqua (lorlatinib) as monotherapy to treat anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) patients.

In December last year, the Committee for Medicinal Products for Human Use (CHMP) had provided a positive opinion to grant EC approval for Lorviqua.

The treatment is indicated for use in adult patients who have not received an ALK inhibitor therapy earlier.

A tyrosine kinase inhibitor (TKI), Lorviqua demonstrated to be greatly active in preclinical lung cancer models harbouring chromosomal rearrangements of ALK.

It is specially developed to hinder tumour mutations that steer resistance to various ALK inhibitors and infiltrate the blood-brain barrier.

The latest approval for Lorviqua as first-line treatment is based on the data from the open-label, randomised, parallel, two-arm Phase III CROWN clinical trial.

It enrolled 296 individuals with priorly untreated advanced ALK-positive NSCLC, who were randomised into a 1:1 ratio to receive Lorviqua or Xalkori monotherapy.

Findings showed that the treatment with Lorviqua lowered disease progression or mortality risk by 72% versus Xalkori (crizotinib).

The secondary endpoint of confirmed objective response rate (ORR) was found to be 76% in the Lorviqua arm versus 58% in the Xalkori arm.

Furthermore, in individuals with measurable brain metastases, 82% of subjects who received Lorviqua had an intracranial response as against 23% treated with Xalkori.

Pfizer Oncology global president and general manager Andy Schmeltz said: “For more than a decade, Pfizer has worked tirelessly in its pursuit to help transform the trajectory for people living with advanced, biomarker-driven lung cancers.

“The European Commission’s approval of Lorviqua as a first-line therapy is a significant milestone that we hope will help bring a needed and meaningful difference to those impacted by this deadly disease in Europe.”

In March last year, the US Food and Drug Administration (FDA) extended Lorbrena’s approval as first-line therapy for ALK-positive NSCLC.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy